Sigma-Aldrich (part ofMilliporeSigma)[5][6] is a brand operating within an American chemical,life science, andbiotechnology company owned by the multinational chemical conglomerateMerck Group. The life sciences business of Merck Group operates asMilliporeSigma in the United States.[7]
Sigma-Aldrich was created in 1975 by themerger of Sigma Chemical Company and Aldrich Chemical Company. It grew through various acquisitions until it had over 9,600 employees and was listed on theFortune 1000. The company has two United States headquarters, inSt. Louis andBurlington, MA and has operations in approximately 40 countries.[8]
In 2015, the multinational chemical conglomerate Merck Group acquired Sigma-Aldrich for $17 billion.[9] The company is currently a part of Merck's life science business and in combination with Merck's earlier acquiredMillipore, operates asMilliporeSigma.[5][6] It is headquartered in Burlington, Massachusetts, United States.[2]
Sigma Chemical Company ofSt. Louis and Aldrich Chemical Company ofMilwaukee were both American specialty chemical companies when they merged in August 1975. The company grew throughout the 1980s and 1990s, with significant expansion in facilities, acquisitions and diversification into new market sectors.[citation needed]
2014 –Merck KGaA announced that it would purchase Sigma-Aldrich for approx. $17 billion (€13.1 billion).[17][18]
November 3, 2014 – Sigma-Aldrich filed a definitive proxy statement with the U.S.Securities and Exchange Commission to hold a special investors meeting regarding approval for the sale to Merck KGaA.[19]
2000 – First Medical Inc., Amelung GmbH, ARK Scientific
2001 – ISOTEC (produces stable isotopes used in basic research and medical diagnostics)[20]
2004 – Ultrafine (a supplier of contract manufacturing services for drug development), Tetrionics (a producer of high potency and cytotoxic active pharmaceutical ingredients)[21]
2005 – JRH Biosciences,[22] an industrial supplier of cell culture products for the pharmaceutical and biotechnology industries; Proligo Group, a global supplier of genomics research tools
2006 – Beijing Superior Chemicals,[23] Iropharm, Pharmorphix,[24] Advanced Separation Technologies[25] (manufacturer of products forchiral chromatography)
2007 – Epichem[26] acquired to expand capabilities in materials sciences and semiconductor markets; Molecular Medicine BioServices acquired to provide large-scale viral manufacturing capabilities; announced alliance with Sangamo BioSciences to develop zinc finger-based laboratory research reagents
2012 – Research Organics Inc., BioReliance (a toxicology and veterinary diagnostics company);[27] BioReliance had previously been acquired byInvitrogen and subsequently sold toAvista Capital Partners.[28]
Sigma-Aldrich Fine Chemicals (SAFC) is the fine chemical supply branch of Sigma-Aldrich specializing in raw materials forcell culture products; customized services for raw materials, manufacturing of activepharmaceutical ingredients.
Sigma Life Science provides products such as customDNA/RNAoligos; custom DNA andLNA probes;siRNA; isotopically-labelled peptides and peptide libraries.
Sigma Advanced Genetic Engineering (SAGE) Labs was a division within Sigma-Aldrich that specializes ingenetic manipulation of in vivo systems for special research and development applications. It was formed in 2008 to investigatezinc finger nuclease technology and its application for disease research models. Located in St. Louis, Missouri, SAGE Labs have developedknockout rats for the study of human diseases and disorders (such as autism), which are sold for up to US$95,000. SAGE also announced its first successful effort in creating a "knockout rabbit".[33] Its facilities include a specific pathogen free, biosecurevivarium as well as research and development labs. SAGE Labs was acquired by Horizon Discovery Group in 2014.[34]
Carbolabs produces research quantities of chemicals produced byphosgenation reactions. The company was acquired in 1998.[35]
BioReliance provides testing and manufacturing services to pharmaceutical and biopharmaceutical companies that span the product cycle from early pre-clinical development to licensed production.The company was acquired by Sigma Aldrich in January 2012.
Jean-Charles Wirth became CEO of the Life Science business of Merck KGaA, Darmstadt, Germany in June 2025 following Matthias Heinzel's departure from the company.[36]